Antibody correlates of protection against Delta infection after vaccination: A nested case-control within the UK-based SIREN study.

Immunity Neutralising Antibodies SARS-CoV-2 SARS-CoV-2 serology Vaccination

Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 14 05 2023
revised: 07 07 2023
accepted: 15 07 2023
pubmed: 10 9 2023
medline: 10 9 2023
entrez: 9 9 2023
Statut: ppublish

Résumé

To investigate serological correlates of protection against SARS-CoV-2 B.1.617.2 (Delta) infection after two vaccinations. We performed a case-control study, where cases were Delta infections after the second vaccine dose and controls were vaccinated, never infected participants, matched by age, gender and region. Sera were tested for anti-SARS-CoV-2 Spike antibody levels (anti-S) and neutralising antibody titres (nAbT), using live virus microneutralisation against Ancestral, Delta and Omicron (BA.1, B.1.1.529). We modelled the decay of anti-S and nAbT for both groups, inferring levels at matched calendar times since the second vaccination. We assessed differences in inferred antibody titres between groups and used conditional logistic regression to explore the relationship between titres and odds of infection. In total, 130 sequence-confirmed Delta cases and 318 controls were included. Anti-S and Ancestral nAbT decayed similarly between groups, but faster in cases for Delta nAbT (p = 0.02) and Omicron nAbT (p = 0.002). At seven days before infection, controls had higher anti-S levels (p < 0.0001) and nAbT (p < 0.0001; all variants) at matched calendar time. A two-fold increase in anti-S levels was associated with a 29% ([95% CI 14-42%]; p = 0.001) reduction in odds of Delta infection. Delta nAbT>40 were associated with reduced odds of Delta infection (89%, [69-96%]; p < 0.0001), with additional benefits for titres >100 (p = 0.009) and >400 (p = 0.007). We have identified correlates of protection against SARS-CoV-2 Delta, with potential implications for vaccine deployment, development, and public health response.

Identifiants

pubmed: 37689394
pii: S0163-4453(23)00380-8
doi: 10.1016/j.jinf.2023.07.007
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

420-427

Subventions

Organisme : Medical Research Council
ID : MR/W02067X/1
Pays : United Kingdom

Informations de copyright

Crown Copyright © 2023. Published by Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. All authors confirmed they have no completing interest to declare.

Auteurs

Ana Atti (A)

UK Health Security Agency, Nobel House, 17 Smith Square, London SW1P 3JR, UK. Electronic address: ana.atti@ukhsa.gov.uk.

Ferdinando Insalata (F)

UK Health Security Agency, Nobel House, 17 Smith Square, London SW1P 3JR, UK.

Edward J Carr (EJ)

UK Health Security Agency, Nobel House, 17 Smith Square, London SW1P 3JR, UK; The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK; UCL Dept of Renal Medicine, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK.

Ashley D Otter (AD)

UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.

Sarah Foulkes (S)

UK Health Security Agency, Nobel House, 17 Smith Square, London SW1P 3JR, UK.

Mary Y Wu (MY)

The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK; Covid Surveillance Unit, The Francis Crick Institute, London, UK.

Michelle J Cole (MJ)

UK Health Security Agency, Nobel House, 17 Smith Square, London SW1P 3JR, UK.

Ezra Linley (E)

UK Health Security Agency, Manchester Royal Infirmary, Oxford Road, Manchester M139WL, UK.

Amanda Semper (A)

UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.

Tim Brooks (T)

UK Health Security Agency, Porton Down, Salisbury SP4 0JG, UK.

Susan Hopkins (S)

UK Health Security Agency, Nobel House, 17 Smith Square, London SW1P 3JR, UK.

Andre Charlett (A)

UK Health Security Agency, Nobel House, 17 Smith Square, London SW1P 3JR, UK.

Rupert Beale (R)

The Francis Crick Institute, 1 Midland Rd, London NW1 1AT, UK; UCL Dept of Renal Medicine, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, UK; Genotype-to-Phenotype UK National Virology Consortium (G2P-UK), UK.

Victoria Hall (V)

UK Health Security Agency, Nobel House, 17 Smith Square, London SW1P 3JR, UK.

Classifications MeSH